Peroxisome proliferator-activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan.
OBJECTIVE
We undertook this study to investigate the effects of olmesartan treatment on PPAR-gamma (PPAR-γ) concentrations and metabolic syndrome (MetS) components in hypertensive (HT) patients.


METHODS
The study included 46 newly diagnosed hypertensive patients and 30 healthy controls. All hypertensive patients were given 40 mg of olmesartan, and they were evaluated weekly in the first month and then twice weekly during follow-up visits. At the end of 3 months, MetS components were assessed and serum PPAR-γ transcription factor concentrations were again measured.


RESULTS
MetS was noted in 80.4% of HT patients. Serum PPAR-γ transcription factor concentration were significantly lower in those with HT compared with the controls (p = 0.005). PPAR-γ concentrations of controls were 1.14-fold higher than hypertensive patients. HDL levels were significantly increased after treatment (p = 0.004), triglyceride, total cholesterol, fasting blood glucose (FBG), and LDL levels were significantly reduced (p <0.05). There was a tendency toward increased PPAR-γ concentrations after treatment, but these were not statistically significant (p = 0.154).


CONCLUSIONS
Olmesartan treatment was found to generate beneficial effects on MetS parameters in HT patients but did not produce any significant increases in serum PPAR-γ transcription factor concentration.
Department of Internal Medicine, Mevlana (RUMI) Universty Hospital, Konya, Turkey. Electronic address: dromerakyurek@gmail.com.
Ömer
Ö
Akyürek
Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.
Erdem
E
Akbal
Department of Internal Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.
Fahri
F
Güneş
Department of Pediatric Endocrinology and Diabetes, School of Medicine, Necmettin Erbakan University, Konya, Turkey.
Nesibe
N
Akyürek
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D047495:PPAR gamma / Q000097:blood*; D013777:Tetrazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D055105:Waist Circumference
D000959:Antihypertensive Agents; D007093:Imidazoles; D047495:PPAR gamma; D013777:Tetrazoles; D014280:Triglycerides; C437965:olmesartan; D002784:Cholesterol
Olmesartan; Peroxisome proliferator-activated receptor